HelpAcademyLoginJoin us as a Member

Vistagen Therapeutics, Inc.

Sign in to save Vistagen Therapeutics, Inc. to a watchlist Sign in to set an alert for Vistagen Therapeutics, Inc.
Tickers
VTGN
Headquarters
Not recorded
SEC CIK
0001411685
Website
Not recorded

Closing prices

Drugs

Drugs from Vistagen Therapeutics, Inc.
DrugIndicationsPhaseNext catalystCT-VCATrials
FasedienolNot yet reviewed: Listed from FDA or ClinicalTrials.gov records; an editor has not checked it yet Sign in to save Fasedienol to a watchlist Social Anxiety Disorder; Social Anxiety Disorder (SAD)Phase 3None scheduledNo published CT-VCA score2

FDA-approved applications

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

SEC filings

SEC filings from Vistagen Therapeutics, Inc., newest first
FormFiledWhat it coversDocument
8-K Current report (8-K) View Current report (8-K) filed 30 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-068627 (opens in a new tab)
8-KEvent 7 Oct 2026 Current report (8-K)
  • Departure or appointment of directors or officers (Item 5.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 9 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-065559 (opens in a new tab)
8-K Current report (8-K)
  • Regulation FD disclosure (Item 7.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 25 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-063510 (opens in a new tab)
8-K Current report (8-K)
  • Other events (Item 8.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 24 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-063316 (opens in a new tab)
8-K Current report (8-K)
  • Other events (Item 8.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 22 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-063046 (opens in a new tab)
8-KEvent 10 Sep 2026 Current report (8-K)
  • Shareholder vote results (Item 5.07)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 11 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-061445 (opens in a new tab)
10-QEvent 30 Jun 2026 Quarterly report (10-Q) View Quarterly report (10-Q) filed 14 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-057116 (opens in a new tab)
8-K Current report (8-K)
  • Results of operations and financial condition (Item 2.02)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 14 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-056953 (opens in a new tab)
8-K Current report (8-K)
  • Regulation FD disclosure (Item 7.01)
  • Other events (Item 8.01)
  • Financial statements and exhibits (Item 9.01)
View Current report (8-K) filed 6 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-054341 (opens in a new tab)
8-KEvent 4 Aug 2026 Current report (8-K)
  • Notice of delisting or listing rule failure (Item 3.01)
View Current report (8-K) filed 5 Aug 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-053304 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Insider transactions

All rows for Vistagen Therapeutics, Inc. on Insider Trades

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
None in this period
Other all other codes
None in this period

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.